Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20985555 | 0.93 | PIK3CA (0.45) | PIK3CAMAPTPOLBNPSR1PIK3CG | |
| SCHEMBL20985492 | 0.90 | PIK3CA (0.46) | PIK3CAMAPTPOLBNPSR1PIK3CG | |
| SCHEMBL18731468 | 0.88 | LMNA (0.58) | PIK3CAMAPTPOLBNPSR1PIK3CG | |
| SCHEMBL20985503 | 0.87 | PIK3CA (0.44) | PIK3CAMAPTPOLBNPSR1PIK3CG | |
| SCHEMBL17678007 | 0.86 | PIK3CA (0.46) | PIK3CAMAPTPOLBNPSR1PIK3CG | |
| SCHEMBL20985506 | 0.86 | PIK3CA (0.48) | PIK3CAMAPTPOLBNPSR1PIK3CG | |
| SCHEMBL17673751 | 0.86 | MAPT (0.50) | PIK3CAMAPTPOLBNPSR1PIK3CG | |
| SCHEMBL17673710 | 0.86 | PIK3CA (0.46) | PIK3CAMAPTPOLBNPSR1PIK3CG | |
| SCHEMBL20985494 | 0.85 | PIK3CA (0.48) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL17678077 | 0.85 | PIK3CA (0.46) | PIK3CAMAPTPOLBNPSR1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | PIK3CA 2468/4885MAPT 3263/4885POLB 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.